Dr Matthias Magoola, the founder and Managing Director of Dei Biopharma Ltd, has been recognised at the prestigious International Molecular Biologist Awards for his contributions to vaccines research.

Dr. Magoola was given the Best Researcher Award for his contribution and honourable achievement in innovative research with his emphasis on using mRNA technology to produce therapeutic drugs and protein vaccines.
The annual biochemistry and molecular genetics award recognizes a scientist whose molecular discovery has improved human health.
Dr. Magoola was recognised after he authored a study titled “Advancing Therapeutic and Vaccine Proteins: Switching from Recombinant to Ribosomal Delivery—A Humanitarian Cause” which is published in the International Journal of Molecular Sciences.
The study emphasises that mRNA technology has emerged as a promising approach to producing therapeutic proteins, offering several advantages over traditional recombinant technology or in vitro translation methods.
“The validation of in vivo messenger RNA (mRNA) technology has been accomplished for COVID-19 vaccines. The bioreactors inside the body, the ribosomes, deliver these proteins at a small cost, since these are chemical products and do not require extensive analytical and regulatory exercises,” the study reads in part.
Commenting on the award on Tuesday, Dr. Magoola said the cost of producing drugs using mRNA technology makes drugs affordable, especially for people in the developing world.
“The cost of therapeutic drugs and making protein vaccines is very expensive, hence not affordable to over 6.5 billion people all over the world,” he said.
“This paper and our cutting-edge technology reveals and teaches what the world needs to do to bring down the cost of these drugs. The research also aims to create harmony among different agencies all over the world that make these products,” he added.
Dr. Magoola said the paper inspires the developing countries to manufacture their own therapeutic drugs.
“We thank them (Molecular Biologist Awards) for selecting our research paper among thousands. We thank the team at DEI that has spent sleepless nights to put this research together,” he said.
This comes after Dr. Magoola was early this year awarded a Doctorate of Philosophy (PhD) from the European International University France.
He also authored a study titled, “Synergistic Approaches in Neurodegenerative Therapeutics: Multi-Target Drug Innovative Interventions for Alzheimer’s Disease,” which has been published in Pharmaceuticals, a peer-reviewed, open-access Journal of Medicinal Chemistry and Related Drug Sciences.
Dr. Magoola holds a Bachelor of Science in Industrial Chemistry from Makerere University Kampala (MUK).
- Advertisement -